<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23642721</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-9875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurologic clinics</Title>
          <ISOAbbreviation>Neurol Clin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Guillain-Barré syndrome and variants.</ArticleTitle>
        <Pagination>
          <StartPage>491</StartPage>
          <EndPage>510</EndPage>
          <MedlinePgn>491-510</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ncl.2013.01.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0733-8619(13)00006-6</ELocationID>
        <Abstract>
          <AbstractText>Guillain-Barré syndrome (GBS) is characterized by rapidly evolving ascending weakness, mild sensory loss, and hyporeflexia or areflexia. Acute inflammatory demyelinating polyneuropathy was the first to be recognized over a century ago and is the most common form of GBS. Axonal motor and sensorimotor variants have been described in the last three decades and are mediated by molecular mimicry targeting peripheral nerve motor axons. Other rare phenotypic variants have been recently described with pure sensory variant, restricted autonomic manifestations, and the pharyngeal-cervical-brachial pattern. It is important to recognize GBS and its variants because of the availability of equally effective therapies in the form of plasmapheresis and intravenous immunoglobulins.</AbstractText>
          <CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dimachkie</LastName>
            <ForeName>Mazen M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Boulevard, Mail Stop 2012, Kansas City, KS 66160, USA. mdimachkie@kumc.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barohn</LastName>
            <ForeName>Richard J</ForeName>
            <Initials>RJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>UL1 TR000001</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>02</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Clin</MedlineTA>
        <NlmUniqueID>8219232</NlmUniqueID>
        <ISSNLinking>0733-8619</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004568" MajorTopicYN="N">Electrodiagnosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23642721</ArticleId>
        <ArticleId IdType="mid">NIHMS549809</ArticleId>
        <ArticleId IdType="pmc">PMC3939842</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ncl.2013.01.005</ArticleId>
        <ArticleId IdType="pii">S0733-8619(13)00006-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326(17):1130–1136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1552914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH, Wijdicks EFM, Truax BT.  In: Guillain-Barré Syndrome, Contemporary Neurology Series. Davis FA, editor. Vol. 34. Philadelphia, PA: 1991.  Comp.</Citation>
        </Reference>
        <Reference>
          <Citation>Landry O. Nore sur la paralysie ascendante aigue. Gaz Hebd Med Paris. 1859;6:472–474.</Citation>
        </Reference>
        <Reference>
          <Citation>Guillain G, Barré JA, Strohl A. Sur un syndrome de radilculonévrite avec hyperalbuminose du liquid céphalo-rachidien sans reaction cellulaire. Remarques sur les catactères cliniques et graphiques de reflexes tendineux. Bull Soc Med Hosp Paris. 1916;40:1462–1470.</Citation>
        </Reference>
        <Reference>
          <Citation>Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol. 1990;27:S7–S12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2194431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653–1666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16271648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997 Dec;176(Suppl 2):S92–S98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9396689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000 Feb 8;54(3):620–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10680793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001 Oct;14(5):605–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11562572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19088488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RD, Cornblath DR, Hughes RA, et al.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neuro. 1998 Nov;44(5):780–788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9818934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKhann GM, Cornblath DR, Ho T, et al.  Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1679153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKhann GM, Cornblath DR, Griffin JW, et al.  Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993 Apr;33(4):333–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8489203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawara K, Kuwabara S, Mori M, et al.  Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 Oct;48(4):624–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11026446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhoodGuillain-Barré syndrome: a reappraisal. Ann Neurol. 1999 Nov;46(5):701–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10553986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatorydemyelinating polyneuropathy. Semin Neurol. 1998;18(1):49–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9562667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–S24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2194422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruts L, Drenthen J, Jongen JL, et al.  Pain in Guillain-Barre syndrome: a long-term follow-upstudy. Neurology. 2010 Oct 19;75(16):1439–1447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20861454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia) N Engl J Med. 1956;255:57–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13334797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007 Jan 24;(1) CD004761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17253522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bickerstaff E, Cloake P. Mesencephalitis and rhombencephalitis. Br Med J. 1951;2:77–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2069534</ArticleId>
            <ArticleId IdType="pubmed">14848512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff ’s brain stem encephalitis and Fisher’s syndrome. J Neurol Sci. 1993;118(1):83–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8229054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odaka M, Yuki N, Yamada M, et al.  Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain Barre syndrome. Brain. 2003;126:2279–2290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12847079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito M, Kuwabara S, Odaka M, et al.  Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008 May;255(5):674–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18274803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986 Nov;43(11):1150–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2946281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias lumbar polyradiculopathy and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994 Jul;51(7):671–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8018039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feasby TE, Gilbert JJ, Brown WF, et al.  An acute axonal form of Guillain-Barré polyneuropathy. Brain. 1986 Dec;109(Pt 6):1115–1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3790970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin JW, Li CY, Ho TW, et al.  Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996 Jan;39(1):17–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8572662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Mishu B, Li Cy, et al.  Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7600081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Gullain-Barre syndromes. Neurology. 2003;61(4):471–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12939419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capasso M, Caporale CM, Pomilio F, et al.  Acute motor conduction block neuropathy: another Gullain-Barre syndrome variant. Neurology. 2003;61:617–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12963751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafer-Macko C, Sheikh KA, Li CY, et al.  Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8619548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin JW, Li CY, Macko C, et al.  Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25:33–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8852937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Willison HJ, Nachamkin I, et al.  Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 1999;45:168–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9989618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allos BM. Association between Campylobacter infection and Guillain-Barré syndrome. J Infect Dis. 1997;176(suppl 2):S25–S127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9396695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magira EE, Papaioakim M, Nachamkin I, et al.  Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain- Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol. 2003;170(60):3074–4080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12626563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al.  Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979;110:105–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">463869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasky T, Terracciano GJ, Magder L, et al.  The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339(25):1797–1802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9854114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine. 2007;25(29):5253–5255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17560693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Preliminary Results: Surveillance for Guillain-Barré Syndrome After Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine --- United States, 2009--2010.  [Accessed on February 3, 2011];Morbidity and Mortality Weekly Report (MMWR) 2010 Jun 2;59(Early Release):1–5. Accessed at  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0602a1.htm?s_cid=mm59e0602a1_e).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20520590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiore AE.  Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. In: Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, editors. MMWR Recomm Rep. RR-8. Vol. 59. Cox NJ: Centers for; 2010. Aug 6, pp. 1–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20689501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry. 2002 Sep;73(3):348–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1738021</ArticleId>
            <ArticleId IdType="pubmed">12185184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985;8(6):528–539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16758578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29(4):565–574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15052622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers JW, Kelly JJ., Jr Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12(6):435–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2657418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RD, Cornblath DR, Hughes RA, et al.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998;44(5):780–788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9818934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiederholt WC, Mulder DW, Lambert EH. The Landry-Guillain-Barré-Srohl Syndrome or polyradiculoneuropathy. Historical Review, report on 97 cases and presetn concepts. Mayo Clin Proc. 1964 Jun;39:427–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14157750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders BJ, Lauer BA, Paisley JW, Reller LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1982;1(8264):131–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6119512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara S, Yuki N, Koga M, et al.  IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neuro. 1998 Aug;44(2):202–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9708542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oomes PG, Jacobs BC, Hazenberg MP, Bänffer JR, van der Meché FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol. 1995 Aug;38(2):170–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7654064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol. 1993;34(2):130–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8338337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psych. 1993;56(2):204–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1014824</ArticleId>
            <ArticleId IdType="pubmed">8437011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology. 1993;43(2):414–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8437711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan GW, Barohn RJ, Bazan C, et al.  Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. Neurology. 1993 Mar;43(3 Pt 1):618–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8451012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996 Sep;47(3):813–817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8797486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Wijdicks EF, Benson E, Multidisciplinary Consensus Group, et al.  Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194–1198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16087757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2893583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35(8):1096–1104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4022342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9066350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004 May 19;291(19):2367–2375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15150209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30(Suppl 1):S9–S14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20480216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Meché FG, Schmitz PI the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–1129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1552913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plasma Exchange Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9014908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology. 1993 May;43(5):872–875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8492939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurolog. 1993 May;43(5):1034–1036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8492921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher. 1997;1:129–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10225757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978 Oct 7;2(8093):750–753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">80682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341(8845):586–5890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8094828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol. 1994 Jun;35(6):749–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8210234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Koningsveld R, Schmitz PI, Meché FG, et al.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004;363(9404):192–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14738791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 23;61(6):736–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14504313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):74–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2169900</ArticleId>
            <ArticleId IdType="pubmed">9436731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dornonville de la Cour C, Jakobsen J. Residual neuropathy in long-term population-based follow-up of Guillain-Barre syndrome. Neurology. 2005 Jan 25;64(2):246–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15668421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vedeler CA, Wik E, Nyland H. The long-term prognosis of Guillain-Barre syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurol Scand. 1997;95:298–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9188906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koeppen S, Kraywinkel K, et al.  Long-term outcome of Guillain-Barre syndrome. Neurocrit Care. 2006;5:235–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17290096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruts L, Drenthen J, Jacobs BC, van Doorn PA Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010 May 25;74(21):1680–1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20427754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neuro. 2009 Nov;66(5):597–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19938102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKhann GM, Griffin JW, Cornblath DR, et al.  Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988 Apr;23(4):347–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3382169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutch Guillain-Barré Study Group. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Neurology. 1999 Aug 11;53(3):598–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10449126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Koningsveld R, Steyerberg EW, Hughes RA, et al.  A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet. 2007;6(7):589–594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17537676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Lingsma HF, Ruts L, et al.  Early recognition of poor prognosis in Gullain-Barre syndrome. Neurology. 2011 Mar 15;76(11):968–975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3059137</ArticleId>
            <ArticleId IdType="pubmed">21403108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, McKhann GM. Patterns of recovery in the Guillain-Barre syndromes. Neurology. 1997 Mar;48(3):695–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9065550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Hsieh ST, Nachamkin I, et al.  Motor nerve terminal degernation provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997;48:717–724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9065554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Kuwabara S, Fukutake T, Haltori T. Intarvenous immunoglobulin thearapy for Miller Fisher syndrome. Neurology. 2007;68(14):1144–1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17404197</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
